



Llywodraeth Cynulliad Cymru
Welsh Assembly Government

Reetan Patel
Project Manager
National Institute for Health and
Clinical Excellence
MidCity Place
71 High Holborn
London
WC1V 6NA

Eich cyf * Your ref
Ein cyf * Our ref

04 May 2007

Dear Reetan

Health Technology Appraisal: Bortezomib for relapsed multiple myeloma

Thank you for your letter of 4 April in relation to the 'responder scheme' arrangements proposed by Janssen-Cilag for the provision of bortezomib (Velcade), within its licensed indication, for relapsed multiple myeloma, in the NHS in England and Wales.

We have studied Janssen-Cilag's proposals in detail discussed this proposal with our colleagues at the Department of Health (DH), and with our policy and professional colleagues at the Assembly, including the Director of Cancer Services.

I have seen the response from Simon Reeve (Head of Clinical and Cost Effectiveness at DH), and fully agree and endorse all the points that were made in his letter.

Yours sincerely

Carl Eley

Head of Healthcare Standards Branch
Quality, Standards and Safety Improvement Directorate
Department for Health and Social Services

CC. Simon Reeve, John Sherriff, Matthew Harpur, Meindert Boysen.



BUDDSODDWR MEWN POBL
INVESTOR IN PEOPLE

Bae Caerdydd • Cardiff Bay
Caerdydd • Cardiff
CF99 1NA